Insulin Market in the US and Europe 2016-2020


#717642

95pages

Technavio

$ 2500

In Stock

About Insulin

Beta cells of the pancreas produce insulin, a hormone that regulates blood glucose levels, by stimulating cells to absorb glucose from the blood. In the cells, glucose is converted into energy, which is used by tissues and muscles to perform their physiological functions. This process is restricted in people with diabetes, resulting in the accumulation of glucose in the blood. This condition is known as hyperglycemia; it damages body tissues over a period, leading to life-threatening health complications such as diabetic retinopathy and diabetic nephropathy. In type 1 diabetes or gestational diabetes, the immune system attacks the pancreatic cells, resulting in little or no insulin production. In type 2 diabetes, the body does not produce sufficient insulin to regulate blood glucose levels. In both type 1 and type 2 diabetes, the individual requires daily doses of insulin along with other medications, depending on the condition. Different types of insulin products, such as human insulin and insulin analogs, are available for insulin replacement therapy.

Technavios analysts forecast the insulin market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:
US
Europe

Technavio's report, Insulin Market in the US and Europe 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Sanofi
Novo Nordisk
Eli Lilly
Other prominent vendors
Adocia
Biocon
Biodel
Biogenomics
Boehringer Ingelheim
Dance Biopharm
Diasome Pharmaceuticals
Exsulin
Generex
Lexicon Pharmaceuticals
Ligand Pharmaceuticals
MannKind
Macrogenics
Merck
Melior Pharmaceuticals
Metabolic Solutions Development Company
NGM Biopharmaceuticals
NuSirt Biopharma
Oramed Pharmceuticals
PhaseBio Pharmaceuticals
Pfizer
Thermalin Diabetes
Tolerion
VeroScience
vTv Therapeutics
Wockhardt
XOMA

Market driver
Advances in insulin delivery technology
For a full, detailed list, view our report

Market challenge
Complexity of insulin production
For a full, detailed list, view our report

Market trend
Increasing price of insulin drugs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.